India's Biovet, a subsidiary of Bharat Biotech, has received a license for its Lumpy Skin Disease (LSD) vaccine, BIOLUMPIVAXIN®, from the Central Drug Standards Control Organization (CDSCO). This vaccine is a significant development for the dairy industry, which has been severely impacted by LSD outbreaks in recent years.
LSD is a contagious disease that affects cattle and buffaloes, causing skin nodules, fever, swollen lymph nodes, decreased milk production, and difficulty in movement. The disease has spread rapidly across India, causing significant economic losses and impacting millions of small-scale farmers.
BIOLUMPIVAXIN® is the world's only marker vaccine for LSD. It offers a high safety and efficacy profile while enabling serological differentiation between naturally infected and vaccinated animals. The vaccine was developed in collaboration with the Indian Council of Agriculture Research-National Research Centre on Equines (ICAR-NRCE) and has been tested to meet the highest global standards.
Vaccination is considered the most effective strategy for controlling LSD. The vaccine instructs the immune system to develop a defense mechanism against the virus, protecting cattle and buffaloes of all age groups. It is recommended to vaccinate animals in advance as a preventive measure.